MXPA05009193A - Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. - Google Patents
Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados.Info
- Publication number
- MXPA05009193A MXPA05009193A MXPA05009193A MXPA05009193A MXPA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A MX PA05009193 A MXPA05009193 A MX PA05009193A
- Authority
- MX
- Mexico
- Prior art keywords
- obesity
- biaryltetrahydroisoquinoline
- piperidines
- treatment
- receptor antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45079903P | 2003-02-28 | 2003-02-28 | |
| PCT/US2004/005780 WO2004078745A1 (en) | 2003-02-28 | 2004-02-26 | Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05009193A true MXPA05009193A (es) | 2005-10-18 |
Family
ID=32962533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05009193A MXPA05009193A (es) | 2003-02-28 | 2004-02-26 | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7498441B2 (enExample) |
| EP (1) | EP1601664B1 (enExample) |
| JP (1) | JP4570165B2 (enExample) |
| CN (1) | CN1777596A (enExample) |
| AR (1) | AR043420A1 (enExample) |
| AT (1) | ATE393766T1 (enExample) |
| CA (1) | CA2517088A1 (enExample) |
| DE (1) | DE602004013427T2 (enExample) |
| ES (1) | ES2305735T3 (enExample) |
| MX (1) | MXPA05009193A (enExample) |
| TW (1) | TW200427679A (enExample) |
| WO (1) | WO2004078745A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121613A2 (en) * | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| NZ590784A (en) | 2008-07-23 | 2012-12-21 | Vertex Pharma | Pyrazolopyridine kinase inhibitors |
| MX2011000837A (es) | 2008-07-23 | 2011-04-05 | Vertex Pharma | Inhibidores de pirazolpiridina cinasa triciclica. |
| MX2011001319A (es) | 2008-08-06 | 2011-04-05 | Vertex Pharma | Inhibidores de aminopiridina cinasa. |
| WO2010129668A1 (en) | 2009-05-06 | 2010-11-11 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
| AU2011209649A1 (en) | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
| EP2582702A1 (en) | 2010-01-27 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
| EP2528917B1 (en) | 2010-01-27 | 2016-10-19 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases |
| WO2017107754A1 (zh) * | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
| CN117343011B (zh) * | 2023-09-28 | 2026-08-07 | 晨伫(杭州)生物科技有限责任公司 | 基于吡唑基-磺酰基-苯基骨架结构的化合物及其制备方法和应用、药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| KR100589872B1 (ko) * | 1997-05-30 | 2006-06-15 | 뉴로서치 에이/에스 | 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| EP1299362A4 (en) | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE |
| CA2443672C (en) * | 2001-04-12 | 2011-03-29 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
| CN100374440C (zh) * | 2002-06-27 | 2008-03-12 | 先灵公司 | 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物 |
-
2004
- 2004-02-26 EP EP04715072A patent/EP1601664B1/en not_active Expired - Lifetime
- 2004-02-26 AT AT04715072T patent/ATE393766T1/de not_active IP Right Cessation
- 2004-02-26 MX MXPA05009193A patent/MXPA05009193A/es active IP Right Grant
- 2004-02-26 WO PCT/US2004/005780 patent/WO2004078745A1/en not_active Ceased
- 2004-02-26 ES ES04715072T patent/ES2305735T3/es not_active Expired - Lifetime
- 2004-02-26 CN CNA2004800109047A patent/CN1777596A/zh active Pending
- 2004-02-26 US US10/788,109 patent/US7498441B2/en not_active Expired - Fee Related
- 2004-02-26 TW TW093104942A patent/TW200427679A/zh unknown
- 2004-02-26 CA CA002517088A patent/CA2517088A1/en not_active Abandoned
- 2004-02-26 JP JP2006508855A patent/JP4570165B2/ja not_active Expired - Fee Related
- 2004-02-26 DE DE602004013427T patent/DE602004013427T2/de not_active Expired - Lifetime
- 2004-02-27 AR ARP040100622A patent/AR043420A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200427679A (en) | 2004-12-16 |
| US20040176355A1 (en) | 2004-09-09 |
| US7498441B2 (en) | 2009-03-03 |
| EP1601664B1 (en) | 2008-04-30 |
| CA2517088A1 (en) | 2004-09-16 |
| WO2004078745A1 (en) | 2004-09-16 |
| JP4570165B2 (ja) | 2010-10-27 |
| JP2006520399A (ja) | 2006-09-07 |
| ATE393766T1 (de) | 2008-05-15 |
| DE602004013427T2 (de) | 2009-06-04 |
| CN1777596A (zh) | 2006-05-24 |
| DE602004013427D1 (de) | 2008-06-12 |
| AR043420A1 (es) | 2005-07-27 |
| ES2305735T3 (es) | 2008-11-01 |
| EP1601664A1 (en) | 2005-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04003858A (es) | Antagonistas de mch para el tratamiento de obesidad. | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
| EE200300415A (et) | Atsüülitud piperidiini derivaadid kui melanokortiin-4 retseptori agonistid ja farmatseutiline kompositsioon | |
| NO20050749L (no) | Nye alkyn-forbindelser med MCH-antagonistisk effekt og medikamenter inneholdende disse forbindelsene | |
| TW200531689A (en) | Therapeutic agents | |
| PH12012501640A1 (en) | Novel compounds as opioid receptor modulators | |
| ATE382353T1 (de) | Substiuierte piperidine als melanocortinrezeptor- modulatoren | |
| SI1735278T1 (sl) | Agenti histamin h receptorja priprava in terapevtska uporaba | |
| TW200504034A (en) | Therapeutic agents | |
| WO2004005262A3 (en) | New neuropeptide y y5 receptor antagonists | |
| MXPA06003363A (es) | Derivados de fenil-piperazina como moduladores de receptores muscarinicos. | |
| UA86621C2 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| WO2006044293A3 (en) | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders | |
| PL1957484T3 (pl) | Antagoniści receptora glukagonu, wytwarzanie i zastosowanie w lecznictwie | |
| TW200621244A (en) | Modulators of muscarinic receptors | |
| TW200633986A (en) | Therapeutic agents | |
| WO2005082893A3 (en) | Histamine h3 receptor antagonists, preparation and therapeutic uses | |
| IS8377A (is) | Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns | |
| MXPA05013596A (es) | Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad. | |
| ATE432702T1 (de) | Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
| ATE393766T1 (de) | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen | |
| MX2007006382A (es) | Moduladores de receptores muscarinicos. | |
| AU2003262926A1 (en) | Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |